Anti-CD20 Treatment Prolongs Syngeneic Islet Graft Survival and Delays the Onset of Recurrent Autoimmune Diabetes

Authors


Address for correspondence: Li Wen, TAC-S141, Mail Box 208020, 330 Cedar Street, New Haven, CT 06520, USA. li.wen@yale.edu

Abstract

Type 1 diabetes is an autoimmune disease characterized by T cell–mediated destruction of pancreatic islet beta cells. Pancreatic islet transplantation with long-term immunosuppressive drug treatment is an accepted therapeutic option for patients with type 1 diabetes suffering from disabling hypoglycemia on insulin treatment. Here we investigated the replacement of immunosuppressive drug treatment with immune tolerance establishment induced by temporary B cell–depletion therapy for islet transplantation. The result suggested that the combined therapy of B cell depletion and syngeneic islet transplantation may reverse the disease in hCD20/NOD mice.

Ancillary